Under this new partnership, CORE Manufacturing will provide manufacturing services, procurement coordination and dual quality control oversight, greatly reducing Palyon’s time to market introduction.

Palyon CEO Michael Sember noted that CORE Manufacturing brings a level of clinical manufacturing experience that will greatly streamline our process and allow our researchers and engineers to focus on developing the next generation of devices, such as an implantable insulin pump.

"Having CORE’s production facility in such close proximity to us will allow for enhanced efficiency, reduced manufacturing coordination costs and speed our path to market," Sember added.

Palyon’s inventive implantable infusion pump platform will offer highly accurate drug delivery rates and incorporate unique safety features including the only sensor-based feedback flow control, refill error detection capability, a non-motorized pumping mechanism that is less susceptible to wear and tear, catheter occlusion detection and a highly favorable MRI profile.